We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




World’s Largest Image-Based AI Models for Digital Pathology and Oncology to Fight Cancer

By LabMedica International staff writers
Posted on 19 Sep 2023
Print article
Image: Paige’s advanced digital pathology and AI software transform the way pathologists work and labs operate (Photo courtesy of Paige)
Image: Paige’s advanced digital pathology and AI software transform the way pathologists work and labs operate (Photo courtesy of Paige)

Two major companies have come together with the goal of revolutionizing cancer diagnosis and treatment by creating the world's most extensive image-based AI models in the fields of digital pathology and oncology.

Paige (New York, NY, USA) and Microsoft (Redmond, WA, USA) are collaborating to build the world's biggest AI model based on images. Paige has already built the first Large Foundation Model, which incorporates over a billion images from half a million pathology slides covering various types of cancer. Together with Microsoft, Paige is working on a new AI model that is far larger than any other image-based AI model currently in existence. Designed with billions of parameters, this model aims to capture the subtle complexities of cancer. This model is expected to serve as the cornerstone for future clinical tools and computational biomarkers that could reshape the fields of oncology and pathology.

For the next stage of this development, Paige plans to add up to four million digitized microscope slides from its enormous, petabyte-scale collection of clinical data, covering multiple cancer types. To make this happen, Paige will leverage Microsoft's advanced supercomputing capabilities to train this colossal AI model. Once ready, the technology is set to be deployed to hospitals and labs worldwide via Microsoft's Azure platform.

“Paige has been at the forefront of innovation since its inception, and by combining Microsoft’s expertise and enormous compute power with Paige’s deep expertise in AI, technology, and digital pathology, we strongly believe we will significantly advance the state-of-the-art in cancer imaging. Through the development of this model, we will help improve the lives of the millions of people who are affected by cancer every day,” said Razik Yousfi, SVP of Technology at Paige.

“Paige technology already goes beyond what is humanly possible today and helps physicians deliver better cancer care with AI support. By realizing the potential of generative AI at unprecedented scale, the Paige model collaboration with Microsoft is a milestone in the history of oncology. It opens a window into the microscopic world with extraordinary fidelity, allowing for not only much higher accuracy but completely novel capabilities,” said Thomas Fuchs, Dr.Sc., Founder and Chief Scientist of Paige.

“By combining Microsoft’s world-class research and cloud infrastructure with Paige’s deep expertise and large-scale data, we are creating new AI models that will enable unprecedented insights into the pathology of cancer,” said Desney Tan, Vice President and Managing Director, Microsoft Health Futures, “Unleashing the power of AI is a game changer in advancing healthcare to improve lives.”

Related Links:
Paige
Microsoft

Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
PSA Test
Humasis PSA Card

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.